Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 22 peer-reviewed journal articles Updated
Ophthalmology

Understanding Your Diagnosis: Vogt-Koyanagi-Harada (VKH) Disease

At a Glance

Vogt-Koyanagi-Harada (VKH) disease is a rare, treatable autoimmune disorder where the body attacks pigment cells in the eyes, skin, and ears. The most important step is starting aggressive treatment within the first 2 to 3 weeks of symptoms to effectively preserve and recover vision.

Finding out you have Vogt-Koyanagi-Harada (VKH) disease can be overwhelming, but understanding the nature of this condition is the first step toward managing it effectively. VKH is a rare autoimmune disorder, which means your immune system—which usually protects you from germs—has mistakenly begun attacking your own body [1].

Specifically, VKH targets melanocytes, the cells responsible for pigment (color) in your skin, hair, and eyes [2]. Because these cells are also found in the lining of your brain (meninges) and your inner ears, the condition can affect multiple parts of your body [2][3].

It is important to acknowledge the emotional toll of this disease. Dealing with sudden vision loss, severe headaches, and the extreme mood swings that often accompany high-dose steroid treatments is physically and mentally exhausting. Your anxiety is valid, but having the right information can help you regain a sense of control.

Three Stabilizing Facts

If you have just been diagnosed, keep these three points in mind:

  1. It is highly treatable: While VKH is serious, most patients respond very well to early, aggressive treatment [4][5].
  2. Vision can be preserved: With prompt care, many people maintain or even recover excellent vision [6][7].
  3. Modern management reduces steroid use: While steroids are the first line of defense, doctors now frequently use “steroid-sparing” medications to control the disease while minimizing side effects [8][9].

Who Does VKH Affect?

VKH is more common in certain ethnic groups, particularly those with more natural skin pigmentation. It is most frequently diagnosed in people of Asian, Hispanic, Native American, Middle Eastern, and Asian Indian descent [10][11][12]. However, it is important to know that VKH can occasionally affect individuals of any ethnicity [10].

Researchers have found a strong genetic link between VKH and a specific marker called HLA-DRB1*0405 [1]. While having this marker doesn’t guarantee someone will develop the disease, it significantly increases the risk in many populations [1]. The condition most often appears in adults between their 20s and 50s [13].

Drug-Induced VKH (The “Melanoma Link”)

In some cases, VKH-like symptoms can be triggered by modern cancer treatments, specifically those used for melanoma (a type of skin cancer) [3].

  • Immune Checkpoint Inhibitors: Drugs like ipilimumab or pembrolizumab work by “turning on” the immune system to fight cancer [14][15]. Sometimes, the immune system becomes so active that it attacks normal melanocytes in the eyes and ears, creating a condition that looks exactly like VKH [3][16].
  • A Positive Sign? Interestingly, in patients being treated for melanoma, developing these VKH-like symptoms is often linked to the treatment working well against the cancer [17][18].

The Importance of the “Window of Opportunity”

Current international consensus emphasizes that the first 2 to 3 weeks after symptoms begin is a critical “therapeutic window” for beginning intense treatment [19]. Starting treatment during this time gives you the best chance of preventing the disease from becoming a long-term issue [20][21].

If you are diagnosed past this window, do not panic. Even if you are diagnosed later, aggressive treatment can still bring the disease under control and protect your vision, though it may require a longer or more complex course of medication [22].

Doctors now use advanced imaging—such as a high-resolution scan of the back of the eye—to see inflammation that might be invisible during a standard exam [20][10]. This allows for more precise monitoring and helps your care team ensure the treatment is working.

Common questions in this guide

What is Vogt-Koyanagi-Harada (VKH) disease?
VKH is a rare autoimmune disorder where your immune system mistakenly attacks melanocytes, the cells that provide pigment to your skin, hair, eyes, and inner ears. This can cause sudden vision changes, severe headaches, and other symptoms.
Can I recover my vision after a VKH diagnosis?
Yes, VKH is highly treatable. With early and aggressive treatment, many people are able to maintain or even fully recover excellent vision.
What are the standard treatments for VKH disease?
The first line of defense is typically steroids to quickly reduce inflammation. Doctors also frequently use steroid-sparing medications to help control the disease long-term while minimizing the side effects of steroids.
Why do some melanoma cancer treatments cause VKH-like symptoms?
Immune checkpoint inhibitors used for melanoma activate your immune system to fight cancer. Sometimes, this heightened immune response mistakenly attacks healthy pigment cells in the eyes and ears, creating inflammation that mimics VKH disease.
Am I currently in the acute or convalescent phase of VKH?
The phase of your disease depends on your specific symptoms and their timeline. The acute phase typically features sudden eye inflammation and vision changes, while the convalescent phase may involve skin and hair pigment changes. Your doctor will determine this based on your examination.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my initial symptoms, am I currently in the 'acute' or 'convalescent' phase of VKH?
  2. 2.If my VKH was triggered by my melanoma treatment, will I need to stop that treatment, or can we manage the eye inflammation while I continue?
  3. 3.What are the specific signs of a 'flare-up' that I should watch for at home?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (22)
  1. 1

    Vogt-Koyanagi-Harada syndrome: what neurologists need to know.

    Lueck CJ

    Practical neurology 2019; (19(4)):278-281 doi:10.1136/practneurol-2018-002165.

    PMID: 30890585
  2. 2

    A case of Vogt-Koyanagi-Harada disease as a sequela of drug reaction with eosinophilia and systemic symptoms.

    Altman K, Shinohara M

    JAAD case reports 2018; (4(9)):863-865 doi:10.1016/j.jdcr.2018.06.019.

    PMID: 30306111
  3. 3

    Vogt-Koyanagi-Harada disease-like posterior uveitis in the course of nivolumab (anti-PD-1 antibody), interposed by vemurafenib (BRAF inhibitor), for metastatic cutaneous malignant melanoma.

    Matsuo T, Yamasaki O

    Clinical case reports 2017; (5(5)):694-700 doi:10.1002/ccr3.911.

    PMID: 28469878
  4. 4

    Vogt-Koyanagi-Harada Disease: A Case Series in a Tertiary Eye Center.

    Shrestha P, Sharma S, Kharel R

    Case reports in ophthalmological medicine 2021; (2021()):8848659 doi:10.1155/2021/8848659.

    PMID: 33552608
  5. 5

    Initial misdiagnosis of Vogt-Koyanagi-Harada disease.

    Shoughy SS, Tabbara KF

    Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological Society 2019; (33(1)):52-55 doi:10.1016/j.sjopt.2018.11.006.

    PMID: 30930664
  6. 6

    Acute phase Vogt-Koyanagi-Harada syndrome resistant to corticosteroid therapy in an adult female patient.

    Kurt ZE, Argin MA

    Archivos de la Sociedad Espanola de Oftalmologia 2025; (100(11)):723-727 doi:10.1016/j.oftale.2025.08.003.

    PMID: 40780442
  7. 7

    Early and Late Treatment Influence on Chorioretinal Microvasculature in Vogt-Koyanagi-Harada Patients Using Optical Coherence Tomography Angiography.

    Huang F, Tan S, Hu J, et al.

    Translational vision science & technology 2024; (13(8)):15 doi:10.1167/tvst.13.8.15.

    PMID: 39120887
  8. 8

    Vogt-Koyanagi-Harada Syndrome: A Diagnostic Conundrum.

    Hussain A, Khurana R

    Cureus 2021; (13(12)):e20138 doi:10.7759/cureus.20138.

    PMID: 35003972
  9. 9

    Early phase Vogt-Koyanagi-Harada Disease in Nepalese Elderly woman: A case report.

    Bahadur BT, Gurung S, Singh S, Aryal M

    Nepalese journal of ophthalmology : a biannual peer-reviewed academic journal of the Nepal Ophthalmic Society : NEPJOPH 2020; (12(23)):146-152 doi:10.3126/nepjoph.v12i1.26202.

    PMID: 32799253
  10. 10

    Vogt-Koyanagi-Harada disease.

    O'Keefe GA, Rao NA

    Survey of ophthalmology 2017; (62(1)):1-25 doi:10.1016/j.survophthal.2016.05.002.

    PMID: 27241814
  11. 11

    Vogt-Koyanagi-Harada Disease, a Rare Entity in Spain: The Challenge of Worldwide Immigration and Globalization.

    Fernández AB, Moyano SP, Husein-ElAhmed H, Juárez AMA

    European journal of case reports in internal medicine 2018; (5(7)):000886 doi:10.12890/2018_000886.

    PMID: 30756049
  12. 12

    Vitiligo as a First Sign of Vogt-Koyanagi-Harada Disease.

    Vukojević M, Vukojevic N, Vuković A, et al.

    Acta dermatovenerologica Croatica : ADC 2023; (31(4)):229-231.

    PMID: 38651852
  13. 13

    Vogt Koyanagi Harada syndrome in a 15-year-old girl, steroids side effects and recurrences.

    Yıldırım G, Çavdarlı C, Özdemir EY, Alp MN

    The Turkish journal of pediatrics 2021; (63(3)):527-532.

    PMID: 34254501
  14. 14

    Case Report: Ipilimumab-induced Multisystem Autoimmune-like Toxicities Suggestive of Vogt-Koyanagi-Harada-like Syndrome.

    Monferrer-Adsuara C, Hernández-Bel L, Hernández-Garfella ML, et al.

    Optometry and vision science : official publication of the American Academy of Optometry 2021; (98(11)):1309-1316 doi:10.1097/OPX.0000000000001798.

    PMID: 34510146
  15. 15

    Vogt-Koyanagi-Harada disease after SARS-CoV-2 infection: Case report and literature review.

    Zou H, Zhang K, Chen X, Sha S

    Immunity, inflammation and disease 2024; (12(4)):e1250 doi:10.1002/iid3.1250.

    PMID: 38661242
  16. 16

    A Case of Vogt-Koyanagi-Harada Disease-Like Uveitis Induced by Nivolumab and Ipilimumab Combination Therapy.

    Minami K, Egawa M, Kajita K, et al.

    Case reports in ophthalmology 2021; (12(3)):952-960 doi:10.1159/000520416.

    PMID: 35082654
  17. 17

    VOGT-KOYANAGI-HARADA-LIKE UVEITIS FOLLOWED BY MELANOMA-ASSOCIATED RETINOPATHY WITH FOCAL CHORIORETINAL ATROPHY AND CHOROIDAL NEOVASCULARIZATION IN A PATIENT WITH METASTATIC CUTANEOUS MELANOMA.

    Ng CC, Alsberge JB, Qian Y, et al.

    Retinal cases & brief reports 2023; (17(1)):18-22 doi:10.1097/ICB.0000000000001113.

    PMID: 33394953
  18. 18

    A Case Report and Literature Review of Vogt-Koyanagi-Harada-Like Uveitis Secondary to Dabrafenib and Trametinib: 4-Year Follow-Up Using Retinal Multimodal Imaging.

    Ucan Gunduz G, Gullulu ZZ, Nizam Tekcan S, et al.

    Ocular immunology and inflammation 2024; (32(10)):2589-2593 doi:10.1080/09273948.2024.2401626.

    PMID: 39250693
  19. 19

    Catching the therapeutic window of opportunity in early initial-onset Vogt-Koyanagi-Harada uveitis can cure the disease.

    Herbort CP, Abu El Asrar AM, Takeuchi M, et al.

    International ophthalmology 2019; (39(6)):1419-1425 doi:10.1007/s10792-018-0949-4.

    PMID: 29948499
  20. 20

    Precise, simplified diagnostic criteria and optimised management of initial-onset Vogt-Koyanagi-Harada disease: an updated review.

    Herbort CP, Tugal-Tutkun I, Abu-El-Asrar A, et al.

    Eye (London, England) 2022; (36(1)):29-43 doi:10.1038/s41433-021-01573-3.

    PMID: 34145419
  21. 21

    Reappraisal of the management of Vogt-Koyanagi-Harada disease: sunset glow fundus is no more a fatality.

    Herbort CP, Abu El Asrar AM, Yamamoto JH, et al.

    International ophthalmology 2017; (37(6)):1383-1395 doi:10.1007/s10792-016-0395-0.

    PMID: 27844182
  22. 22

    Predictive Factors for Uveitis Refractory to Treatment in Initial-Onset Acute Vogt-Koyanagi-Harada Disease.

    Gin TJ, Surendran SA, Rogers SL, Lim LL

    Clinical & experimental ophthalmology 2025; (53(6)):627-636 doi:10.1111/ceo.14538.

    PMID: 40254294

This page provides educational information about Vogt-Koyanagi-Harada (VKH) disease. Always consult your ophthalmologist or specialist for medical advice and treatment planning tailored to your specific symptoms.

Get notified when new evidence is published on Vogt-Koyanagi-Harada disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.